Results 181 to 190 of about 113,185 (266)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. [PDF]

Leukemia
Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H.   +9 more
europepmc   +1 more source

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE‐STOP219 study

British Journal of Haematology, EarlyView.
Summary Treatment‐free remission (TFR) is now a key goal for chronic‐phase chronic myeloid leukaemia (CML‐CP) after achievement of a prolonged deep molecular response. About half of these patients can remain in remission without treatment, whereas those who relapse must resume lifelong therapy.
Noriyoshi Iriyama, Naoto Takahashi, Katsumichi Fujimaki, Takaaki Ono, Masuho Saburi, Masahide Yamamoto, Fumihiko Kimura, Eisei Kondo, Nobuyuki Aotsuka, Hiroki Yokoyama, Seiichiro Katagiri, Yosuke Minami, Maho Ishikawa, Yachiyo Kuwatsuka, Masatomo Miura, Akiko M. Saito, Toshiki I. Saito, Itaru Matsumura, Yasushi Miyazaki, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Hitoshi Kiyoi   +22 more
wiley   +1 more source

Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia. [PDF]

Haematologica
Cheng F, Li W.
europepmc   +1 more source

Mosaic chromosomal alterations and relation to haematological cancer in two large Danish cohorts

British Journal of Haematology, EarlyView.
Summary Mosaic chromosomal alterations (mCAs) are large somatic gains, losses and copy‐neutral loss of heterozygosity identified in the peripheral blood, which represent a relatively unexplored spectrum of clonal haematopoiesis. We aimed to describe mCAs in two large Danish cohorts with extensive long‐term registry‐based follow‐up and examine ...
Cecilie Velsoe Maeng, Pei Meng, Mathias Heldbo, Olafur Davidsson, Morten Munk Johansen, Sigrún Thorsteinsdóttir, Jojo Biel‐Nielsen Dietz, Ragnar Pétur Kristjansson, Ole Birger Vesterager Pedersen, Erik Sørensen, Christian Erikstrup, Christina Mikkelsen, Nanna Brøns, Henrik Ullum, Bitten Aagaard, Mie Topholm Bruun, Estrid Høgdall, DBDS Research Consortium, CHB Research Consortium, Bo Porse, Simon Husby, Sisse R. Ostrowski, Henrik Hjalgrim, Kirsten Grønbæk   +23 more
wiley   +1 more source

Macrocytosis as an Early Pharmacodynamic Marker of Imatinib Efficacy in Chronic Myeloid Leukemia. [PDF]

J Clin Med
Yaman F, Pinar IE, Isik S, Yavasoglu F, Gunduz E, Uskudar Teke H, Andic N.   +6 more
europepmc   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, EarlyView.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Inhibition of Pellino-1 reverts the progression and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]

Cell Death Dis
Zhou Q, Xu G, Li Z, Xu Y, Guan J, Li Z, Li M, Zu T, Li Y, Lu C, Ji C, Zhao B.   +11 more
europepmc   +1 more source

Chronic myeloid leukemia [PDF]

, 2020
openaire   +1 more source